It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Background
Circadian patterns of migraine attacks have been reported by patients but remain understudied. In animal models, circadian phases are generally not taken into consideration. In particular, rodents are nocturnal animals, yet they are most often tested during their inactive phase during the day. This study aims to test the validity of CGRP-induced behavioral changes in mice by comparing responses during the active and inactive phases.
Methods
Male and female mice of the outbred CD1 strain were administered vehicle (PBS) or CGRP (0.1 mg/kg, i.p.) to induce migraine-like symptoms. Animals were tested for activity (homecage movement and voluntary wheel running), light aversive behavior, and spontaneous pain at different times of the day and night.
Results
Peripheral administration of CGRP decreased the activity of mice during the first hour after administration, induced light aversive behavior, and spontaneous pain during that same period of time. Both phenotypes were observed no matter what time of the day or night they were assessed.
Conclusions
A decrease in wheel activity is an additional clinically relevant phenotype observed in this model, which is reminiscent of the reduction in normal physical activity observed in migraine patients. The ability of peripheral CGRP to induce migraine-like symptoms in mice is independent of the phase of the circadian cycle. Therefore, preclinical assessment of migraine-like phenotypes can likely be done during the more convenient inactive phase of mice.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details

1 University of Iowa, Department of Molecular Physiology and Biophysics, Iowa City, USA (GRID:grid.214572.7) (ISNI:0000 0004 1936 8294); Veterans Administration Health Center, Center for the Prevention and Treatment of Visual Loss, Iowa City, USA (GRID:grid.214572.7)
2 University of Iowa, Department of Molecular Physiology and Biophysics, Iowa City, USA (GRID:grid.214572.7) (ISNI:0000 0004 1936 8294)
3 University of Iowa, Neuroscience Program, Iowa City, USA (GRID:grid.214572.7) (ISNI:0000 0004 1936 8294)
4 University of Iowa, Department of Molecular Physiology and Biophysics, Iowa City, USA (GRID:grid.214572.7) (ISNI:0000 0004 1936 8294); University of Texas at Dallas, Present address: Brain and Behavior Sciences, Center for Advanced Pain Studies, Richardson, USA (GRID:grid.267323.1) (ISNI:0000 0001 2151 7939)
5 University of Iowa, Department of Pharmacology, Iowa City, USA (GRID:grid.214572.7) (ISNI:0000 0004 1936 8294)
6 University of Iowa, Department of Molecular Physiology and Biophysics, Iowa City, USA (GRID:grid.214572.7) (ISNI:0000 0004 1936 8294); Veterans Administration Health Center, Center for the Prevention and Treatment of Visual Loss, Iowa City, USA (GRID:grid.214572.7); University of Iowa, Department of Neurology, Iowa City, USA (GRID:grid.214572.7) (ISNI:0000 0004 1936 8294)